by Filipe Pacheco for Bloomberg

“A Chinese maker of drugs used in cancer treatments surged in Hong Kong after an initial public offering priced at the top of a marketed range, a rare case of strong demand for a listing in the financial hub of the year…”

Continue reading at the original source, linked here.